

4. Mitteilungsblatt

Nr. 5

Mitteilungsblatt der Medizinischen Universität Wien
Studienjahr 2021/2022
4. Stück; Nr. 5

Bevollmächtigungen

5. Bevollmächtigungen gem. § 27 Abs. 2 UG

5. Bevollmächtigungen gem. § 27 Abs. 2 UG

Gemäß § 27 Abs. 2 UG werden folgende Bevollmächtigungen erteilt:

Auftragsnummer	Projekttitle	Organisationseinheit	Projektleiter(in)
FA731B2002	Establishment of a Comprehensive Cancer Center Pancreatic Cancer Registry	Allgemeinchirurgie_731	Schindl Martin
FA731B2201	Efficacy of NHS-PEG coated collagen patch (Hemopatch) for prevention of bile leaks after liver resection - a power analysis.	Allgemeinchirurgie_731	Schwarz Christoph
FA731E0608	Evaluating CYP3A function after orthotopic liver transplantation using a microdose of midazolam as a marker substance	Allgemeinchirurgie_731	Berlakovich Gabriela
FA731X0101	TOPMOST	Allgemeinchirurgie_731	Stremitzer Stefan
FA738A0810	A microbiological examination of HCU used routinely in the General Hospital of Vienna	Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie_738	Kimberger Oliver
FA738C0703	Argatroban Monitoring in kritisch kranken Patienten: Evaluierung eines neuen Ecarin basierten Bedside-Test	Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie_738	Steinlechner Barbara
FA613A0901	The epigenetics of the spermatozoa of HIV-1 infected men	Anatomie und Zellbiologie_310	Wossidlo Mark
FA746A1501	A Two-Year, Three-Arm, Randomized, Double-Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab versus	Augenheilkunde und Optometrie_746	Pollreis Andreas

	Aflibercept in Adult Patients with Visual Impairment due to Diabetic Macular Edema		
FA746A1503	YOSEMITE GR40349 - a phase III, multicenter, randomized, doublemasked, active comparator controlled study to evaluate the efficacy and safety of RO6867461 in patients with diabetic macular edema	Augenheilkunde und Optometrie_746	Pollreisz Andreas
FA746A1640	A Phase 2, Randomized Placebo-Controlled, Double-Masked Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRX, an Antisense Inhibitor of Complement Factor B, in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)	Augenheilkunde und Optometrie_746	Sacu Gülhan Stefan
FA746A1641	A 56-week phase IIIb/IV, open-label, one-arm extension study to assess the efficacy and safety of brolocizumab 6 mg in a Treat-to-Control regimen with maximum treatment intervals up to 20 weeks for the treatment of patients with neovascular age-related macular degeneration who have completed the CRTH258A2303 (TALON) study	Augenheilkunde und Optometrie_746	Sacu Gülhan Stefan
FA746A2504	Central reading of imaging material in a 52 weeks double blind, randomized and placebo controlled trial	Augenheilkunde und Optometrie_746	Gerendas Bianca

	evaluating the effect of oral KIN001 150 mg plus pioglitazone 10 mg daily on injection frequency of Standard of Care (SOC) in patients with diagnosed unilateral wet AMD undergoing a treat and extend regimen		
FA746A2606	A 2-year randomized, 3-arm, double-blind, non-inferiority study comparing the efficacy and safety of ofatumumab and siponimod versus fingolimod in pediatric patients with multiple sclerosis followed by an open-label extension	Augenheilkunde und Optometrie_746	Pemp Berthold
FA746A3107	General Research Funding - Funding Agreement	Augenheilkunde und Optometrie_746	Leydolt Christina
FA746A3303	A phase 2 trial of the efficacy and safety of the interleukin-17A inhibitor ABY-035 in the treatment and prevention of relapse/recurrence of non-infectious intermediate, posterior or pan-uveitis, including an initial pilot phase	Augenheilkunde und Optometrie_746	Funk Marion
FA654A0201	Pharmakokinetik von "black market" Myostatin	Biomedizinische Forschung_308	Podesser Bruno Karl
FA727A0614	Phase Ib Open Label Multi Center, Dose Escalation and Expansion Study of APN401 in Patients with Advanced Solid Tumors	Blutgruppenserologie und Transfusionsmedizin_727	Worel Nina
FA727A0615	Herstellung APN401	Blutgruppenserologie und Transfusionsmedizin_727	Worel Nina

FA727A0901	A Phase 2, Open-Label Study of INCB050465 in Participants With Autoimmune Hemolytic Anemia	Blutgruppenserologie und Transfusionsmedizin_727	Körmöczi Günther
FA722A1002	Persisting inflammation in treated atopic dermatitis skin – a potential mediator of disease recurrence.	Dermatologie_722	Brunner Patrick
FA722B2401	T cell-mediated versus anti-TNF-alpha or anti-IL-17A antibody-induced proliferative response of human dendritic cells in psoriasis.	Dermatologie_722	Tittes Julia
FA722C0904	Unraveling the mechanisms of octenidine dihydrochloride efficacy on human skin.	Dermatologie_722	Elbe-Bürger Adelheid
FA722C1703	CemiSkin: Eine Nicht-Interventionelle Zwei-Kohorten Studie zur Untersuchung von Patienten mit fortgeschrittenem Plattenepithelkarzinom der Haut, die entweder mit Cemiplimab oder anderen Ansätzen behandelt werden.	Dermatologie_722	Geusau Alexandra
FA751C0122	TESARO Inc., A Phase 3 Randomized Double-Blind Trial of Maintenance with Niraparib Versus Placebo in Patients with Platinum Sensitive Ovarian Cancer, PR-30-5011-C, PAREXEL # 210204	Frauenheilkunde_751	Reinhaller Alexander
FA751C0133	A Phase III Randomized, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab in Combination with	Frauenheilkunde_751	Reinhaller Alexander

	Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib in Newly Diagnosed Advanced Ovarian Cancer Patients		
FA751C0211	Tumor Suppressor Protein Aggregation Determines Response to Olaprib	Frauenheilkunde_751	Zeillinger Robert
FA751C0517	A randomized, double-blind, open for active comparator, parallel-group, multicenter Phase 2b study to assess the efficacy and safety of three different doses of P2X3 antagonist (BAY 1817080) versus placebo and elagolix 150 mg in women with symptomatic endometriosis	Frauenheilkunde_751	Wenzl René
FA751C0518	A double-blind, randomized, placebo-controlled multicenter study to investigate efficacy and safety of elinzanetant for the treatment of vasomotor symptoms over 26 weeks in postmenopausal women	Frauenheilkunde_751	Wenzl René
FA751C0667	Austrian BRCA-associated metastatic breast cancer registry	Frauenheilkunde_751	Singer Christian
FA751C0671	A Phase 2 Study of TAS-117 in Patients with Advanced Solid Tumors Harboring Germline PTEN Inactivating Mutations	Frauenheilkunde_751	Singer Christian
FA751C1204	Video-assisted genetic counseling for hereditary breast and ovarian cancer	Frauenheilkunde_751	Pfeiler Georg

FA751C1206	Eine epidemiologische, prospektive Beobachtungsstudie zur Erhebung von Evidenz aus der Versorgungsrealität von Patientinnen und Patienten mit HR+/HER2-Fortgeschrittenem Brustkrebs, die in der Erstlinie gemäß aktuellem Behandlungsstandard mit einer endokrin-basierten Palbociclib-Kombinationstherapie behandelt werden	Frauenheilkunde_751	Pfeiler Georg
FA751D0711	A randomized, double-blind, open for active comparator, parallel-group, multicenter Phase 2b study to assess the efficacy and safety of three different doses of P2X3 antagonist (BAY 1817080) versus placebo and elagolix 150 mg in women with symptomatic endometriosis	Frauenheilkunde_751	Ott Johannes
FA744A0202	Effects of locally applied glucocorticoids and selective glucocorticoid receptor agonists on the inner ear in an animal model	Hals-, Nasen- und Ohrenkrankheiten_744	Arnoldner Christoph
FA744B0504	Provision of EAN Observations	Hals-, Nasen- und Ohrenkrankheiten_744	Berger Uwe
FA744C0104	Biofilmbildung auf Grenz- und Oberflächen aktiver Implantate und Elektrostimulation zur Therapie von Rekurrensparesen	Hals-, Nasen- und Ohrenkrankheiten_744	Schneider-Stickler Berit
FA731C2201	Preventing Oxidative stress induced Systemic Inflammation after invasive Cardiac	Herzchirurgie_732	Wiedemann Dominik

	surgery with Alkaline Phosphatase (APPIRED III)		
FA731C2301	Pumpe für ECCO2R - Anteil Herzchirurgie	Herzchirurgie_732	Granegger Marcus
FA732A0302	Medtronic Cardiac Surgery Post Market Clinical Follow-up Registry	Herzchirurgie_732	Andreas Martin
FA732A0402	Noninvasive Cardiovascular Diagnosis of Patients With Fully Magnetically Levitated Blood Pumps	Herzchirurgie_732	Schlöglhofer Thomas
FA732A0501	Feasibility study of a novel cavopulmonary assist device	Herzchirurgie_732	Granegger Marcus
FA629A0402	Life-long cross-generational priming of the hypothalamus for obesity - FOODFORLIFE	Hirnforschung_360	Harkany Tibor
FA711A0165	Randomisierte Studie zur Wirksamkeit einer Cetuximab-Reexposition bei Patienten mit metastasiertem kolorektalem Karzinom (RAS Wildtyp), welche auf eine Erstlinien-Behandlung mit FOLFIRI plus Cetuximab ein Ansprechen zeigten	Innere Medizin I_711	Preusser Matthias
FA711A0312	Randomized Clinical Study of Haplo-Identical Donors versus Unrelated Donors in Hematopoietic Stem Cell Transplant Patients with Acute Myeloid Leukemia	Innere Medizin I_711	Burgmann Heinz
FA711B0537	A randomized double-blind, placebo-controlled study of LEE011 in combination with letrozole for the treatment of	Innere Medizin I_711	Preusser Matthias

	postmenopausal women with hormone receptor positive, HER2-negative, advanced breast cancer who received no prior therapy for advanced disease		
FA711B0542	A Phase 3, Multicenter, Open-label, Randomized Study of nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Subjects With Surgically Resected Pancreatic Adenocarcinoma	Innere Medizin I_711	Preusser Matthias
FA711B0595	Safety and Effectiveness of Ramucirumab in Patients with Advanced Gastric Cancer in the European Union and North America: A Prospective Observational Registry (I4T-MC-JVDD)	Innere Medizin I_711	Preusser Matthias
FA711B0601	"A Phase 3 Clinical Trial of Pembrolizumab (MK-3475) in First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (MK3475-048)"	Innere Medizin I_711	Preusser Matthias
FA711B0707	An Open-Label, Randomized Phase 3 Trial of Combinations of Nivolumab, Elotuzumab, Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma	Innere Medizin I_711	Valent Peter

FA711B0708	An Open Label, Randomized, Two Arm Phase III Study of Nivolumab in Combination with Ipilimumab versus Extreme Study Regimen (cetuximab + cisplatin/carboplatin + fluorouracil) as First Line Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)	Innere Medizin I_711	Preusser Matthias
FA711B0810	A prospective, open, randomized, phase II study of carboplatin/olaparib in the pre-operative treatment of patients with triple-negative primary breast cancer which exhibit the features of positive homologous recombination deficiency (HRD) status	Innere Medizin I_711	Preusser Matthias
FA711B0902	STEAM: Study of TG02 in Elderly Newly Diagnosed or Adult Relapsed Patients with Anaplastic Astrocytoma or Glioblastoma: A Phase Ib Study	Innere Medizin I_711	Preusser Matthias
FA711B0907	DISEASE-DRUG MATCHING AND BIOMARKER DISCOVERY STUDY USING Allcyte's PHARMACOSCOPY	Innere Medizin I_711	Preusser Matthias
FA711B0924	POWER: Real world data of 1st line Panitumumab treatment in combination with chemotherapy in non-resectable wild type (WT) RAS Metastatic Colorectal Cancer (mCRC). Subjects in Austria, Bulgaria,	Innere Medizin I_711	Preusser Matthias

	Croatia, Czech Republic, Hungary, Poland, Slovenia, Romania, Russia. An observational ambidirectional study		
FA711B0975	a phase 3, randomized, open-label, controlled study of Cabozantinib (XL 184) in combination with Atezolizumab vs second novel hormonal therapy (NHT) in subjects with high-risk, metastatic castration-resistant Prostate Cancer	Innere Medizin I_711	Preusser Matthias
FA711B0976	Brustkrebsakademie	Innere Medizin I_711	Preusser Matthias
FA711B0977	Phase 1b open-label. Multi-center. Dose escalation and expansion study of APN401 in patients with advanced solid tumors	Innere Medizin I_711	Preusser Matthias
FA711B0978	A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for the Treatment of Chemotherapy-Candidate Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Locally Recurrent Inoperable or Metastatic Breast Cancer (KEYNOTE-B49)	Innere Medizin I_711	Preusser Matthias
FA711B0979	Eine Phase-1b-Studie zur Beurteilung der Sicherheit und Wirksamkeit von AMG 757 in Kombination mit AMG 404 bei	Innere Medizin I_711	Preusser Matthias

	Patienten mit kleinzelligem Lungenkrebs (SCLC)		
FA711B0980	A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 2a or R/R Marginal Zone Lymphoma (INCMOR0208-301_inMIND)	Innere Medizin I_711	Preusser Matthias
FA711B0981	A Phase 2 Randomized Double-blind Study of Relatlimab plus Nivolumab in Combination with Chemotherapy vs. Nivolumab in Combination with Chemotherapy as First Line Treatment for Participants with Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)	Innere Medizin I_711	Preusser Matthias
FA711B0982	Glioblastoma (GBM) adaptive, global, innovative learning environment (AGILE) is an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed (ND) and recurrent GBM.	Innere Medizin I_711	Preusser Matthias

FA711B0983	Eine randomisierte Phase II Studie zur Zweitlinienbehandlung mit liposomalem Irinotecan und 5-FU im Vergleich zu liposomalen Irinotecan mit S1 bei Patienten mit einem metastasierten Pankreaskarzinom die eine Erstlinientherapie mit Gemcitabine erhalten haben	Innere Medizin I_711	Preusser Matthias
FA711B0984	A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 160 in Subjects with Non-Small Cell Lung Cancer	Innere Medizin I_711	Preusser Matthias
FA711C0120	Vonicog alfa (recombinant von Willebrand factor) Treatment Outcomes in von Willebrand Disease in Selected European Countries: a Retrospective Chart Review Study	Innere Medizin I_711	Kyrle Paul Alexander
FA711C0632	JHTB-Studie - A Phase 2 Study of LY2784544 in Patients with Myeloproliferative Neoplasms	Innere Medizin I_711	Valent Peter
FA711C1086	Eine Phase-1-Studie zur Bestimmung der Sicherheit, Verträglichkeit, Pharmakokinetik und Pharmakodynamik von BCX9930 in Einzeldosen und Mehrfachdosen bei gesunden Probanden und bei Patienten mit paroxysmaler nächtlicher Hämoglobinurie (PNH)	Innere Medizin I_711	Valent Peter
FA711C1316	Emicizumab in Patients with acquired	Innere Medizin I_711	Valent Peter

	hemophilia A: Multicenter, single- arm, open-label clinical trial		
FA711D0305	CAPNETZ - Epidemiologische Studie und Aufbau einer Biobank zur ambulant erworbenen Pneumonie	Innere Medizin I_711	Burgmann Heinz
FA711D0309	The Moyen-Ogooué Pregnancy and Birth Cohort	Innere Medizin I_711	Burgmann Heinz
FA712A0306	Early Stage: Combination of Artemisinin with 5- ALA/heme biosynthesis modulators as novel therapy for brain tumors and other cancers	Innere Medizin I_711	Berger Walter
FA712A0908	Assessment of immune checkpoint- associated biomarkers (PD-L1, PD-L2, IRF1, and CD8A) in formalin- fixed, paraffin- embedded tissue samples in a GeneXpert test cartridge	Innere Medizin I_711	Filipits Martin
UE71106004	Personalkostenförderu ng	Innere Medizin I_711	Valent Peter
FA714B0382	MULTivessel Immediate versus STAged Revascularization in Acute Myocardial Infarction - The MULTISTARS AMI Trial	Innere Medizin II_714	Lang Irene
FA714B0383	Akute Machbarkeitsstudie zur Beurteilung der Sicherheit und Leistung des Aria CV Akutsystems für PH bei Patienten mit pulmonaler Hypertonie der WHO-Gruppen 2	Innere Medizin II_714	Lang Irene

	und 3 - Aria CV WHO 2&3 PH Acute Study		
FA714B0384	Balloon pulmonary angioplasty versus pulmonary endarterectomy in patients with chronic thromboembolic pulmonary hypertension: a non-inferiority randomized trial (GO CTEPH)	Innere Medizin II_714	Lang Irene
FA714B0529	EU H2020 731532 - ReGenHeart	Innere Medizin II_714	Pavone-Gyöngyösi Mariann
FA714B1522	A long-term, multicenter, single-arm, open-label extension of the SERENADE study, to assess the safety and efficacy of macitentan in subjects with heart failure with preserved ejection fraction and pulmonary vascular disease	Innere Medizin II_714	Kastner Johannes
FA714B1709	Nicht-interventionelle Studie zur Edoxaban-Therapie in der klinischen Routinepraxis bei Patienten mit nicht-valvulärem Vorhofflimmern (ETNA-AF-Europe)	Innere Medizin II_714	Gwechenberger Marianne
FA714B2013	Support for a claim extension for NT-proBNP in diabetes in China	Innere Medizin II_714	Hülsmann Martin
FA714B2405	GEMS-AF	Innere Medizin II_714	Pezawas Thomas
FA714B2406	Post Market Clinical Follow up Studie	Innere Medizin II_714	Pezawas Thomas
FA714B2711	Factor XA-inhibition in RENal patients with non-valvular atrial	Innere Medizin II_714	Bergler-Klein Jutta

	fibrillation Observational study		
FA714B2715	Postmarket Study - TriageTru	Innere Medizin II_714	Bergler-Klein Jutta
FA714B3108	Optimizing Beta Blocker Dosage in Women Using the Wearable Cardioverter Defibrillator - OPT-BB Women	Innere Medizin II_714	Kastner Johannes
FA714B3801	NOAH - Afnet 6: Non- vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes	Innere Medizin II_714	Bergler-Klein Jutta
FA714B4401	Stress bei medizinischen Personal und Kontrollen	Innere Medizin II_714	Sponder Michael
FA714B4903	Eine randomisierte, doppelblinde, placebokontrollierte Phase-III-Studie zu Pembrolizumab plus Chemotherapie im Vergleich zu Placebo plus Chemotherapie zur Behandlung von Teilnehmern mit einem Hormonrezeptor- positiven, humanen epidermalen Wachstumsfaktor- Rezeptor-2-negativen (HR+/HER2-), lokal rezidivierenden, inoperablen oder metastasierenden Brustkrebs, der ein Chemotherapie- Kandidat ist (KEYNOTE- B49)	Innere Medizin II_714	Kastl Stefan
FA714B5101	Iron and chronic thrombosis	Innere Medizin II_714	Campean Ioana- Alexandra
FA714B5301	Diagnostic accuracy of artificial intelligence algorithms in the diagnosis of cardiac	Innere Medizin II_714	Nitsche Christian

	tracer uptake on bone scintigraphy		
FA714C0309	„A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone on the reduction of cardiovascular morbidity and mortality in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease in addition to standard of care“ und der Bayer-Nummer IMP1 7530 (FIGARO)	Innere Medizin II_714	Schernthaler Gerit
FA714C0709	Head-to-Head Comparison of SIROLimus versus Paclitaxel Drug-Eluting Balloon Angioplasty in the Femoropopliteal Artery	Innere Medizin II_714	Schlager Oliver
FA714D0504	Wirksamkeit und Sicherheit von Benralizumab im Real-World Setting in Patienten mit schwerem eosinophilem Asthma in Wien - (BEHAVE) 1.1. Projekttitle (Englisch): The real-world effectiveness and safety of Benralizumab in patients with severe eosinophilic asthma in Vienna - (BEHAVE)	Innere Medizin II_714	Idzko Marco
UE71406015	Comprehensive imaging and patient management training with regard to edge-to-edge mitral and tricuspid valve procedures	Innere Medizin II_714	Mascherbauer Julia

FA716B0311	A phase 3 randomized, multicenter, multinational, double-blinded study comparing the efficacy and safety of repeated biweekly infusions of neo GAA (GZ402666) and α -glucosidase in treatment naive patients with late onset Pompe disease	Innere Medizin III_716	Kautzky-Willer Alexandra
FA716B0616	A randomized, double-blind, placebo-controlled, multicenter study to assess the safety and efficacy of individually titrated oral doses of runcaciguat in subjects with clinical diagnosis of chronic kidney disease with diabetes and/or hypertension and at least one cardiovascular comorbidity“, CONCORD Study und der Bayer-Nummer BAY 1101042	Innere Medizin III_716	Kautzky-Willer Alexandra
FA716B1404	“A Randomized, Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Paltusotine in Subjects with Acromegaly Treated with Long-acting Somatostatin Receptor Ligands“, Protocol Number CRN00808-09	Innere Medizin III_716	Vila Greisa
FA716C0826	A Phase 1/2, Baseline-controlled, Non-randomised, Open-label, Single-ascending Dose Study of a Novel Adeno-associated Viral Vector (FLT190) in Patients with Fabry Disease	Innere Medizin III_716	Sunder- Pläßmann Gere

FA716C0827	Eine multizentrische, einarmige, offene Studie zur Beurteilung der Wirksamkeit und Sicherheit von oralem, zweimal täglichem LNPO23 bei erwachsenen aHUS-Patienten, die nicht mit einer Komplement-Inhibitor-Therapie behandelt werden	Innere Medizin III_716	Sunder-Plaßmann Gere
FA716C0915	Safety, Tolerability and Efficacy of Monoclonal CD38 Antibody Felzartamab in Late Antibody-Mediated Renal Allograft Rejection – A Phase 2 Pilot Trial	Innere Medizin III_716	Böhmig Georg
FA716C1019	An International, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Arrhythmia-Related Cardiovascular Outcomes in Participants on Chronic Hemodialysis with Recurrent Hyperkalemia, (DIALIZE-Outcomes)	Innere Medizin III_716	Oberbauer Rainer
FA716C1020	Genomics-based immunological risk stratification in kidney transplantation	Innere Medizin III_716	Oberbauer Rainer
FA716D0718	Förderung des Aufbaues einer umfangreichen Datenbank zur translationalen Forschung auf dem Gebiet der Immundefekte	Innere Medizin III_716	Scheinecker Clemens
FA716D1503	Interleukin 17 and osteoclastogenesis in psoriatic arthritis: The effects of IL-17 blockade	Innere Medizin III_716	Hayer Silvia

FA716D2001	Funding IMI project RTCure	Innere Medizin III_716	Bonelli Michael
FA716E0830	An open-label extension and safety monitoring study of moderate to severe	Innere Medizin III_716	Trauner Michael
FA716E0838	An Open-Label, Multicenter Study to Evaluate Long-Term Outcomes With ABT- 450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ-I)”	Innere Medizin III_716	Trauner Michael
FA716E0840	A Randomized, Double- Blind, Placebo- Controlled, Phase 3 Study of Ramucirumab and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma and Elevated Baseline Alpha- Fetoprotein (AFP) Following First- LineTherapy With Sorafenib	Innere Medizin III_716	Trauner Michael
FA716E0843	AN OPEN-LABEL EXTENSION AND SAFETY MONITORING STUDY OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE PREVIOUSLY ENROLLED IN THE ETROLIZUMAB PHASE III PROTOCOL GA29144	Innere Medizin III_716	Trauner Michael

FA716E0844	A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ETROLIZUMAB AS AN INDUCTION AND MAINTENANCE TREATMENT FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE	Innere Medizin III_716	Trauner Michael
FA716E0858	A randomized, multi-center phase III study of Nivolumab versus Sorafenib as first-line treatment in patients with advanced HCC	Innere Medizin III_716	Trauner Michael
FA716E0944	Efficacy of sGC agonists in biliary cirrhosis and portal hypertension	Innere Medizin III_716	Trauner Michael
FA716E0949	Consultancy Agreement Boehringer Ingelheim International GmbH	Innere Medizin III_716	Trauner Michael
FA716E0994	A multinational observational registry collecting data on the profile of patients with chronic hepatitis D virus infection receiving treatment with buleviritide	Innere Medizin III_716	Trauner Michael
FA716E0995	ICARUS –IBD: International study of COVID-19 Antibody Response Under Sustained immune suppression in Inflammatory Bowel Disease	Innere Medizin III_716	Trauner Michael
FA716E0996	FW-UC-001, A phase I/IIa, three-stage study to investigate the safety, the efficacy and the	Innere Medizin III_716	Trauner Michael

	pharmacokinetics of Niclosamide enemas in subjects with active Ulcerative Proctitis or Ulcerative Procto-Sigmoiditis		
FA716E0997	A Phase 2 Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study to Evaluate the Safety and Efficacy of Oral PN 943 in Subjects with Moderate to Severe Active Ulcerative Colitis	Innere Medizin III_716	Trauner Michael
FA716E0998	A Multicenter, Single-Arm Prospective Study to Evaluate Safety and Efficacy of GLE/PIB 8-Week Treatment in Adult and Adolescent Subjects with Acute Hepatitis C Virus (HCV) Infection	Innere Medizin III_716	Trauner Michael
FA716E0999	A Phase 2, Double-Blind, Randomized, Parallel Group Study Evaluating the Efficacy, Safety, and Tolerability of Obeticholic Acid Administered in Combination with Bezafibrate in Subjects with Primary Biliary Cholangitis Who Had an Inadequate Response or Who Were Unable to Tolerate Ursodeoxycholic Acid	Innere Medizin III_716	Trauner Michael
FA716E1001	A Multicenter, Randomized, Double-Blind, Parallel-Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction and Maintenance Therapy for Moderately to	Innere Medizin III_716	Trauner Michael

	Severely Active Crohn's Disease		
FA716E1002	A Randomized, Double-blind Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral NX-13 in Active Ulcerative Colitis	Innere Medizin III_716	Trauner Michael
FA716E1003	A Phase 3, Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients with Crohn's Disease	Innere Medizin III_716	Trauner Michael
FA716E1006	A Phase 3b, Randomized, Double-blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Re-induction Therapy With Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease	Innere Medizin III_716	Trauner Michael
FA716F0106	Optimal gender-specific treatment paths on healthcare multiplex networks	Innere Medizin III_716	Kautzky-Willer Alexandra
FA781B0807	Europäische Wachstumsforen Datenbank zu Increlex	Kinder- und Jugendheilkunde_781	Häusler Gabriele
FA781B2707	Adaptive simulation based on real time cognitive load, affective and biometric measures: virtual reality serious game application in realistic paediatric emergency skill training environment (VR-PMES)	Kinder- und Jugendheilkunde_781	Wagner Michael
FA781B3301	PIMIENTO Precision Medicine in IntravENTricular hemorrhage for Outcome prediction	Kinder- und Jugendheilkunde_781	Göral Katharina

FA781B3401	"Gene Fusions" - New Detectable Targets in Liquid Biopsy Samples of Pediatric Brain Tumors (Oncomine Clinical Grant Program)	Kinder- und Jugendheilkunde_781	Madlener Sibylle
FA781D0433	The European Paediatric Network for Haemophilia Management and the PedNet Haemophilia Registry	Kinder- und Jugendheilkunde_781	Male-Dressler Christoph
FA781D0435	Prospective Multi-Center Evaluation of the Duration of Therapy for Thrombosis in Children - KIDS-DOTT	Kinder- und Jugendheilkunde_781	Male-Dressler Christoph
FA781D0438	Safety and Efficacy of nonacog beta pegol (N9-GP) in Previously Untreated Patients with Hemophilia B	Kinder- und Jugendheilkunde_781	Male-Dressler Christoph
FA781D0439	A phase III, prospective, multicenter, uncontrolled, open-label clinical study to determine the efficacy, safety and tolerability of rVWF with or without ADVATE in the treatment and control of bleeding episodes, the efficacy and safety of rVWF in elective and emergency surgeries, and the pharmacokinetics (PK) of rVWF in children diagnosed with severe Von Willebrand Disease	Kinder- und Jugendheilkunde_781	Male-Dressler Christoph
FA781D0440	A prospective, randomized, open label, multicenter study of the safety of Apixaban versus vitamin K antagonist or LMWH in pediatric subjects with congenital or acquired heart disease requiring chronic	Kinder- und Jugendheilkunde_781	Male-Dressler Christoph

	anticoagulation for thromboembolism prevention		
FA781D0441	Nicht interventionelle Studie bei einer Langzeitbehandlung mit Haemoctin SDH	Kinder- und Jugendheilkunde_781	Male-Dressler Christoph
FA781D0442	Safety and Efficacy of turoctocog alfa pegol (N8-GP) in Previously Untreated Patients with Haemophilia A	Kinder- und Jugendheilkunde_781	Male-Dressler Christoph
FA781D0604	A randomized, open-label, active controlled, safety and extrapolated efficacy study in pediatric subjects requiring anticoagulation for the treatment of a venous thromboembolic event	Kinder- und Jugendheilkunde_781	Male-Dressler Christoph
FA781F0112	Forschungsunterstützung Novo Nordisk	Kinder- und Jugendheilkunde_781	Häusler Gabriele
FA781F0603	A Global, Multi-Center, Long-Term, Observational Survey of Patients with Hunter Syndrome (Mucopolysaccharidosis II)	Kinder- und Jugendheilkunde_781	Konstantopoulou Vassiliki
FA781F0606	DAS ALPHA-MANNOSIDOSE-REGISTER: Eine multizentrische, internationale, nicht-interventionelle, prospektive Kohorte bei Alpha-Mannosidose-Patienten	Kinder- und Jugendheilkunde_781	Konstantopoulou Vassiliki
FA781F1202	Pädiatrische Patienten mit XLH: Inzidenz und Management im klinischen Alltag von XLH und assoziierten Komorbiditäten	Kinder- und Jugendheilkunde_781	Raimann Adalbert
FA781F1603	Newborn Screening for Spinal Muscular Atrophy in Austria	Kinder- und Jugendheilkunde_781	Zeyda Maximilian

UE78106007	OKids	Kinder- und Jugendheilkunde_781	Greber-Platzer Susanne
UE78106014	EOPD - Mobiler Psychologischer Dienst	Kinder- und Jugendheilkunde_781	Leiss Ulrike
UE78106017	Durchführung von studentischen Sitzwachen im Rahmen des § 49 Abs 2 ÄrzteG an der Epilepsie-Monitoring-Unit bei PatientInnen mit EEG Monitoring	Kinder- und Jugendheilkunde_781	Berger Angelika
UE78106020	Personalkosten Prolacta	Kinder- und Jugendheilkunde_781	Binder Christoph
UE78106021	Neurofeedback bei Neurofibromatose	Kinder- und Jugendheilkunde_781	Pletschko Thomas
FA729A0150	A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of BIVV009 in Patients with Primary Cold Agglutinin Disease Without a Recent History of Blood Transfusion (Cadenza)	Klinische Pharmakologie_729	Jilma Bernd
FA729A0154	A Randomized, Open-Label, Multi-Centre, Active Control Study Investigating the Efficacy and Safety of Imlifidase in Eliminating Donor Specific Anti-HLA Antibodies in the Treatment of Active Antibody-Mediated Rejection in Kidney Transplant Patients	Klinische Pharmakologie_729	Jilma Bernd
FA729A0255	A randomized, parallel arm, placebo-controlled, double-blind study to evaluate safety and clinical efficacy of G-PUR treatment in patients with irritable bowel syndrome with diarrhea (IBS-D)g	Klinische Pharmakologie_729	Wolzt Michael

FA729A0260	Randomised, double-blind, placebo-controlled phase 1 dose-escalation study of FluBHPVE6E7 in HPV-16 infected women with normal cytology or low-grade cervical intraepithelial neoplasia	Klinische Pharmakologie_729	Wolzt Michael
FA729A0263	Eine randomisierte, doppelblinde, Placebo kontrollierte Phase I Studie (erstmals am Menschen) mit adaptiven Design und ansteigenden Einzeldosierungen gefolgt von Kohorten mit ansteigender Mehrfachdosierung zur Evaluierung der Sicherheit, Verträglichkeit und Pharmakokinetik von REM0046127 an gesunden Probanden.	Klinische Pharmakologie_729	Wolzt Michael
FA729A1028	FULL Plasma, ELF and intraperitoneal pharmacokinetics of ceftazidime-avibactam in critically ill and peritoneal dialysis patients	Klinische Pharmakologie_729	Zeitlinger Markus
FA729A1035	Antibiotic Distribution and Recovery in Tissue (AB-DiRecT)	Klinische Pharmakologie_729	Zeitlinger Markus
FA729A1047	Single dose pharmacokinetics of cefiderocol in plasma and soft tissues of healthy volunteers	Klinische Pharmakologie_729	Zeitlinger Markus
FA729A1048	A phase 1, double-blind, placebo-controlled, dose-escalation study to assess the safety and tolerability of inhaled APN01	Klinische Pharmakologie_729	Zeitlinger Markus

FA729A1049	rhSOD in COVID-19	Klinische Pharmakologie_729	Zeitlinger Markus
FA729A1050	Investigation of Pharmacokinetics of Cefiderocol in Severely Burned Patients	Klinische Pharmakologie_729	Zeitlinger Markus
FA729A1309	Determination of physical compatibility of IntelliGel eye drops with contact lenses	Klinische Pharmakologie_729	Schmidl Doreen
FA729A1403	Improving brain distribution of drugs targeted to the brain	Klinische Pharmakologie_729	Langer Claus Oliver
FA729A1501	Feasibility of preclinical Cangrelor treatment: a pilot trial	Klinische Pharmakologie_729	Gelbenegger Georg
FA729A1502	Beta-blockade with landiolol in out-of-hospital cardiac arrest: a randomized, double-blind, placebo-controlled pilot trial	Klinische Pharmakologie_729	Gelbenegger Georg
FA729A1601	A Single/Multiple Ascending Dose Phase 1 Study Of The Safety, Tolerability, And Pharmacokinetics Of Intranasal 2-Deoxy-D-Glucose In Normal Healthy Volunteers	Klinische Pharmakologie_729	Haiden Nadja
FA793A0808	Oxiope Thrombosis	Labormedizin_793	Binder Christoph
FA793A2001	Development of therapeutics targeting mutant CALR	Labormedizin_793	Kralovics Robert
FA793A2102	checkit!	Labormedizin_793	Luf Anton
FA793A2501	FW-UC-001, A phase I/IIa, three-stage study to investigate the safety, the efficacy and the pharmacokinetics of Niclosamide enemas in subjects with active Ulcerative Proctitis or Ulcerative Procto-Sigmoiditis	Labormedizin_793	Schweiger Christian

FA793B0115	Nachweis von Galactomannan	Labormedizin_793	Willinger Birgit
FA793B0116	Testung von Cefiderocol bei multiresistenten gramnegativen Stäbchen	Labormedizin_793	Willinger Birgit
FA793C0203	Asymptomatic SARS-CoV-2 NPS samples	Labormedizin_793	Straßl Robert Paul
FA605A0906	Innovationsscheck: Additive Fertigung und messtechnische Unterstützung für einen HNO Teststand	Medizinische Physik und Biomedizinische Technik_340	Rafolt Dietmar
FA605A1005	Peripheral Nerve Pacing to Restore Blink in a Large Animal Model of Facial Paralysis	Medizinische Physik und Biomedizinische Technik_340	Bijak Manfred
FA605A2002	Ultraschall-Translationsinvarianz für Bildgütephantome	Medizinische Physik und Biomedizinische Technik_340	Hummel Johann
FA605A2302	Pumpe für ECCO2R - Anteil BMT	Medizinische Physik und Biomedizinische Technik_340	Schima Heinrich
UE60506009	Optimierte CBCT Bildgebung	Medizinische Physik und Biomedizinische Technik_340	Birkfellner Wolfgang
FA602A0109	Platform for Innovation of Procurement and Procurement of Innovation	Medizinische Statistik, Informatik und Intelligente Systeme_303	Stamm Tanja
FA632A0507	Planung und Auswertung der Studie "Beobachtung von Sicca-PatientInnen, die mit HYLO-PROTECT versus HYLO-FRESH behandelt werden" (HYPRODA)	Medizinische Statistik, Informatik und Intelligente Systeme_303	Ristl Robin
FA632A0601	Usage of Parenteral Nutrition in European Hospitals (NutritionDay)	Medizinische Statistik, Informatik und Intelligente Systeme_303	Hiesmayr Jörg Michael
FA632A0603	NutritionDay	Medizinische Statistik, Informatik und Intelligente Systeme_303	Hiesmayr Jörg Michael
FA632A0603	NutritionDay	Medizinische Statistik, Informatik und Intelligente Systeme_303	Hiesmayr Jörg Michael
FA632A0604	nutritionDay	Medizinische Statistik, Informatik und Intelligente Systeme_303	Hiesmayr Jörg Michael

FA660A1104	Statistische Beratung und Feedback bei Studien zu den Themen Digital Health, Big Data und Patientensicherheit - LBI-DHPS	Medizinische Statistik, Informatik und Intelligente Systeme_303	Heinze Georg
UE60206001	Systematic literature review on the prevention, screening for and management of RA-related interstitial lung disease (RA-ILD)	Medizinische Statistik, Informatik und Intelligente Systeme_303	Stamm Tanja
FA761A1132	Umwelt und MS	Neurologie_761	Berger Thomas
FA761A1133	A phase III multicenter, randomized, double-blind, double-dummy, parallel-group study to evaluate the efficacy and safety of Fenebrutinib compared with Ocrelizumab in adult patients with primary progressive Multiple Sclerosis (FENTREPID)	Neurologie_761	Berger Thomas
FA761A1134	A phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with primary progressive multiple sclerosis - EFC16035 PERSEUS mit der Substanz SAR442128	Neurologie_761	Berger Thomas
FA761A1135	The epidemiology and clinical characterisation of 5q-linked spinal muscular atrophy in Austria	Neurologie_761	Berger Thomas
FA761A1136	A randomised double-blind placebo-controlled clinical trial investigating the effect and safety of oral semaglutide in subjects with early Alzheimer's disease (EVOKE)	Neurologie_761	Berger Thomas

FA761A1137	A randomised double-blind placebo-controlled clinical trial investigating the effect and safety of oral semaglutide in subjects with early Alzheimer's disease (EVOKE plus)	Neurologie_761	Berger Thomas
FA761A1138	A phase 2 trial to investigate the efficacy, safety and tolerability of Efgartigimod PH20 SC in adult patients with chronic inflammatory demyelinating Polyneuropathy (CIDP)	Neurologie_761	Berger Thomas
FA796A0503	Decoding cellular senescence in glioblastoma	Neurologie_761	Wöhler Adelheid
FA796A0601	Multimodal decoding of CD163 immune cell function in progressive MS	Neurologie_761	Hametner Simon
UE76106005	NEW WAYS TO ASSESS TREATMENT RESPONSE IN PATIENTS WITH MULTIPLE SCLEROSIS: COMBINED ASSESSMENT OF RETINAL THINNING, NEUROFILAMENTS AND OLFACTORY THRESHOLD (RNOT-SCORE) A PROSPECTIVE, OBSERVATIONAL STUDY	Neurologie_761	Bsteh Gabriel
FA761A1112	Bewertung des SONAS-Ultraschallgeräts in der Untersuchung der bilateralen zerebralen Durchblutung bei Patienten nach akutem Schlaganfall	Neurologie-Klinik_761	Berger Thomas
FA761A1116	A phase 4 randomized clinical trial of Andexanet Alfa (Andexanet Alfa for Injection) in acute intracranial hemorrhage	Neurologie-Klinik_761	Berger Thomas

	in patients receiving an oral factor Xa inhibitor.		
UE76106002	Experimental neuroimmunology in Multiple Sclerosis	Neurologie-Klinik_761	Berger Thomas
FA728A1201	Kardiovaskuläre Forschung und Biomarker in der Notfallmedizin "IVDR Performance Evaluation TROPT Sensitive Intermediate Precision cobas h 232 CIM RD005289"	Notfallmedizin_728	Niederdöckl Jan
FA608A0323	LOHA	Pathobiochemie und Genetik_306	Scheiber-Mojdehkar Barbara
FA681A0503	Reprogramming fibroblasts from patients with RETT syndrome into functionally active neurons for in vitro protein replacement therapy	Pathobiochemie und Genetik_306	Steinkellner Hannes
FA791A0717	Charakterisierung von malignen Tumorerkrankungen mittels Foundation One Assay (F1 Testung)	Pathologie_791	Müllauer Leonhard
FA791A0718	Status of PIK3CA mutations from archival primary tumor and matched archival metastatic samples in HR+/HER2- breast cancer from the biobank established	Pathologie_791	Müllauer Leonhard
FA791A1006	Nationale Vernetzungsplattform für personalisierte Medizin "Plattform"	Pathologie_791	Kain Renate
FA791A1007	Prospective, Randomized, Multi-Center Study to Evaluate Treatment of subjects with Occlusive Disease with a Novel	Pathologie_791	Kain Renate

	PAcliTaxel-CoatEd Angioplasty Balloon in Below-The-Knee (BTK) arteries		
FA791A1111	"„A phase II, single arm, multicenter trial to determine the efficacy and safety of CTL019 in adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)“ Zentrum Prof. Jäger"	Pathologie_791	Simonitsch-Klupp Ingrid
FA791A1146	"MOR208C310: A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL)"	Pathologie_791	Simonitsch-Klupp Ingrid
FA791A1147	A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Tafasitamab plus Lenalidomide in Addition to Rituximab versus Lenalidomide in Addition to Rituximab in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Grade 1-3a or R/R Marginal Zone Lymphoma (MZL)	Pathologie_791	Simonitsch-Klupp Ingrid

FA791A1418	TALAPRO-1: A Phase 2, Open-Label, Response Rate Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer Who Previously Received Taxane-Based Chemotherapy and Progressed on at Least 1 Novel Hormonal Agent (Enzalutamide and/or Abiraterone Acetate/Prednisone) Zentrum Prof. Kramer / Urologie	Pathologie_791	Haitel Andrea
FA791A1420	CA209-650: Phase 2 Trial of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men with Metastatic Castration-Resistant Prostate Cancer	Pathologie_791	Haitel Andrea
FA791A1423	A Phase 3 Study or Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations	Pathologie_791	Haitel Andrea
FA791A1632	eMonarchHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib plus Standard Adjuvant Endocrine Therapy in Participants with High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy” (“Clinical Study or	Pathologie_791	Bago-Horvath Zsuzsanna

	Study") protocol I3Y-MC-JPCW		
FA791A1633	A Phase 2 Study of TAS-117 in Patients with Advanced Solid Tumors Harboring Germline PTEN Inactivating Mutations	Pathologie_791	Bago-Horvath Zsuzsanna
FA791A1634	A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for the Treatment of Chemotherapy-Candidate Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Locally Recurrent Inoperable or Metastatic Breast Cancer (KEYNOTE-B49) (MK-3475-B49-Site number 1601)	Pathologie_791	Bago-Horvath Zsuzsanna
FA791A2107	The AIM-HN and SEQ-HN Study: A 2 Cohort, Non-comparative, Pivotal Study Evaluating the Efficacy of Tipifarnib in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC) with HRAS Mutations (AIM-HN) and the Impact of HRAS Mutations on Response to First Line Systemic Therapies for HNSCC (SEQ-HN) Zentrum Prof. Füreder	Pathologie_791	Pammer Johannes
FA791A2604	A Phase 1b Study Evaluating the Safety and Efficacy of AMG 757	Pathologie_791	Geleff Silvana

	in Combination with AMG 404 in Subjects with Small Cell Lung Cancer (SCLC)		
FA791A2703	A prospective, randomised, Controlled, Open-label, Multicentre phase III study to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with ¹⁷⁷ Lu-Edotreotide compared to targeted molecular therapy with Everolimus in patients with inoperable, progressive, somatostatin receptor-positive (SSTR+), neuroendocrine tumours of gastroenteric or pancreatic origin (GEP-NET) – short title ‘COMPETE study’ Zentrum Prof. Haug	Pathologie_791	Mazal Peter
FA791A3405	„PSMAAddition: An International Prospective Open-label, Randomized, Phase III Study comparing ¹⁷⁷ Lu-PSMA-617 in combination with Standard of Care, versus Standard of Care alone, in adult male patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC)” - interner Studiencode CAAA617C12301	Pathologie_791	Comperat Eva Maria
FA791A3406	PSMAfore: A phase III, Open-label, Multi-Center, Randomized Study Comparing ¹⁷⁷ Lu-PSMA-617 vs. a Change of androgen receptor-	Pathologie_791	Comperat Eva Maria

	directed therapy in the Treatment of Taxane Naïve Men with Progressive Metastatic Castrate Resistant Prostate Cancer“ - interner Studiencode CAAA617B12302		
FA623A0220	INDUCTION OF HBV VIRUS NEUTRALIZING ANTIBODIES IN HEALTHY VACCINE NAIVE ADULTS AND NON-RESPONDERS AND IN PATIENTS CHRONICALLY INFECTED WITH HBV USING VVXX001	Pathophysiologie, Infektiologie und Immunologie_370	Wiedermann-Schmidt Ursula
FA624A0213	Immunomodulatory payload evaluation for oncolytic immunotherapy IV	Pathophysiologie, Infektiologie und Immunologie_370	Steinberger Peter
FA624A0403	Etablierung eines molekularen Interaktionsassays (MIA) als In-House-Tests für die Bestimmung von blockierenden SARS-CoV-2 Antikörpern	Pathophysiologie, Infektiologie und Immunologie_370	Pickl Winfried
FA644A0112	Entwicklung von Azithromycin-Derivaten zur medikamentösen Behandlung von Infektionen durch SARS-CoV-2 und anderen behüllten Viren	Pathophysiologie, Infektiologie und Immunologie_370	Stockinger Hannes
FA644A0509	Vienna Water Ressource Systems 2020+	Pathophysiologie, Infektiologie und Immunologie_370	Kirschner Alexander
FA644A0701	The Impact of Giardia spp.as a reference pathogen in urban water systems	Pathophysiologie, Infektiologie und Immunologie_370	Sommer Regina
FA648A1705	Point-of-care device base on KETs for diagnosis of food allergies	Pathophysiologie, Infektiologie und Immunologie_370	Untersmayr-Elsenhuber Eva
FA648A1708	HDHL-INTIMIC Knowledge Plattform on Food, Diet, Intestinal	Pathophysiologie, Infektiologie und Immunologie_370	Untersmayr-Elsenhuber Eva

	Microbiomics and Human Helth		
FA648A2301	Quantitative multiplexing for assessment of immune checkpoints by Tissue Image Cytometry	Pathophysiologie, Infektiologie und Immunologie_370	Mechtcheriakov a Diana
UE64806003	Knochenforschung	Pathophysiologie, Infektiologie und Immunologie_370	Pietschmann Peter
UE72606001	Spende der Amgen GmbH - Unterstützung der wissenschaftlichen Tätigkeit (ausschließlich Personalkosten)	Physikalische Medizin, Rehabilitation und Arbeitsmedizin_726	Kerschanschindl Katharina
FA625A1105	T20K Autoimmunity	Physiologie und Pharmakologie_350	Schabbauer Gernot
FA641A0120	SCLC-BET2 Amendment No.3	Physiologie und Pharmakologie_350	Hamilton Gerhard
FA731F0703	RANGER®: A Multicenter Registry Study of Avance® Nerve Graft Utilization, Evaluations and Outcomes in Peripheral Nerve Injury Repair	Plastische, Rekonstruktive und Ästhetische Chirurgie_734	Radtke Christine
FA763B1102	ESCAPE TRD 54135419TRD3013	Psychiatrie und Psychotherapie_763	Frey Richard
FA763C0404	"EU FP7 PSYSCAN Translating neuroimaging findings from research into clinical practice"	Psychiatrie und Psychotherapie_763	Wancata Johannes
FA763C0701	Thiaminsubstitution bei Alkoholabhängigkeit: Evaluierung aktueller Behandlungsstandards	Psychiatrie und Psychotherapie_763	Amering Michaela
FA766A0501	Exploring Experiences of Young Adults with the 22q11 Deletion Syndrome: A Pilot Study	Psychoanalyse und Psychotherapie_766	Löffler-Stastka Henriette
FA636A0602	National Healthcare Systems Changes and Challenges - Access, Inequity and Socio-Economic Inequality, a Comparison between Kenya and Zambia	Public Health_380	Jirovsky-Platter Elena

FA646A0302	Community Engagement und Vulnerabilitäten in der Bewältigung von Epidemien	Public Health_380	Kutalek Ruth
FA647A0116	Air Pollution in Kosovo - impact on human health, behaviour change and policy recommendations	Public Health_380	Moshammer Hanns
FA771B0416	Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer	Radiologie und Nuklearmedizin_771	Helbich Thomas
FA771B0826	Phase 3, prospective, randomized, multi-center clinical study comparing the safety and efficacy of BAX 855 following PK-guided prophylaxis targeting two different FVIII trough levels in subjects with severe Hemophilia A	Radiologie und Nuklearmedizin_771	Herold Christian
FA771B0877	An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 with TL-895 in Subjects with Relapsed/Refractory Myelofibrosis and of KRT-232 in Janus-associated Kinase Inhibitor Intolerant Myelofibrosis	Radiologie und Nuklearmedizin_771	Herold Christian
FA771B1201	Somatom Force	Radiologie und Nuklearmedizin_771	Apfaltrer Paul
FA771B1601	PSMAfore: A phase III, Open-label, Multi-Center, Randomized Study Comparing ¹⁷⁷ Lu-PSMA-617 vs. a Change of androgen receptor-directed therapy in the Treatment of Taxane Naïve Men with Progressive Metastatic Castrate Resistant	Radiologie und Nuklearmedizin_771	Baltzer Pascal

	Prostate Cancer - CAAA617B12302		
FA771B1602	PSMAddition: An International Prospective Open-label, Randomized, Phase III Study comparing 177Lu-PSMA-617 in combination with Standard of Care, versus Standard of Care alone, in adult male patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC) - interner Studiencode CAAA617C12301	Radiologie und Nuklearmedizin_771	Baltzer Pascal
FA771D0512	A prospective, randomised, Controlled, Open-label, Multicentre phase III study to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-Edotreotide compared to targeted molecular therapy with Everolimus in patients with inoperable, progressive, somatostatin receptor-positive (SSTR+), neuroendocrine tumours of the pancreas (P-NET).	Radiologie und Nuklearmedizin_771	Wolf Florian
FA771D0801	Somatom Force	Radiologie und Nuklearmedizin_771	Schernthaner Rüdiger
FA771D1001	A multicentre, double blind, randomised, placebo controlled, Phase II trial to evaluate Resminostat for maintenance treatment of patients with advanced stage (Stage IIB IVB) mycosis	Radiologie und Nuklearmedizin_771	Loewe Christian

	fungoides (MF) or Sézary Syndrome (SS) that have achieved disease control with systemic therapy – the RESMAIN Study		
FA771D1301	DEDALUS - Weiterentwicklung der Lehrfilmsammlung	Radiologie und Nuklearmedizin_771	Toth Daniel
FA771E0508	Precision medicine for breast cancer: multi-omics towards predicting complete remission and avoiding surgery	Radiologie und Nuklearmedizin_771	Langs Georg
FA771E0803	1000-Ideen TAI 676-N	Radiologie und Nuklearmedizin_771	Bogner Wolfgang
FA771E1003	PATHFNDR: Paltusotine Acromegaly Therapy Featuring a Non-Invasive Daily Regimen	Radiologie und Nuklearmedizin_771	Furtner-Srajer Julia
FA771G0243	Herstellung von Radiometallmarkierten Arzneimitteln mittels automatisierter Systeme und deren Qualitätskontrolle	Radiologie und Nuklearmedizin_771	Hacker Marcus
FA771G0247	N.c.a. Lu-177 in radiopharmazeutischen Präparationen - operatives Labormanagement.	Radiologie und Nuklearmedizin_771	Hacker Marcus
FA771G0261	PSMAfore: A phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of androgen receptor-directed therapy in the Treatment of Taxane Naïve Men with Progressive Metastatic Castrate Resistant Prostate Cancer	Radiologie und Nuklearmedizin_771	Hacker Marcus
FA771G0262	PSMAddition: An International Prospective Open-label, Randomized, Phase III Study comparing 177Lu-	Radiologie und Nuklearmedizin_771	Hacker Marcus

	PSMA-617 in combination with Standard of Care, versus Standard of Care alone, in adult male patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC)		
FA771G0263	The PIAF Trial on Arterial 18FFDG PET Imaging Patients with History of Myocardial Infarction and Elevated Inflammatory Status	Radiologie und Nuklearmedizin_771	Hacker Marcus
FA774A1201	"A randomized, double-blind placebo-controlled, Phase 3 study of Debio 1143 in combination with platinum-based chemotherapy and standard fractionation intensity-modulated radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck, suitable for definitive chemoradiotherapy (TrilynX)." ("Trial")	Radioonkologie_774	Herrmann Harald
FA103A0010	Austria Allergy Research Cluster (AARC), Konzeptantrag, Rudolf Valenta	Rektorat_100	Fritz Michaela
FA103A0011	CoE Molecular precision medicine, Konzeptantrag, Christoph Bock	Rektorat_100	Fritz Michaela
FA103A0012	CoE Neuronal circuits in health and disease, Konzeptantrag, Tibor Harkany	Rektorat_100	Fritz Michaela
FA731T0601	The molecular biological signalling of the trepostinil's anti-fibrotic action in idiopathic pulmonary fibrosis	Thoraxchirurgie_733	Lambers Christopher

FA670F0204	Effects of one-piece individual abutment on peri-implant soft tissue and bone level: A fully digital workflow	Universitätszahnklinik Wien GmbH_991	Rausch-Fan Xiaohui
FA670F0205	Characterization of absorbable gradient membrane for periodontal soft tissue augmentation procedures in vitro	Universitätszahnklinik_670	Rausch-Fan Xiaohui
FA711D0133	Platelet Rich Fibrin in combination with topical antibiotics	Urologie_743	Thalhammer Florian
FA743A0111	A phase III, multicenter, randomized study of Atezolizumab (Anti-PD-L1 Antibody) in combination with Enzalutamide versus Enzalutamide alone in patients with metastatic castration-resistant prostate cancer after failure of an Androgen synthesis inhibitor and failure of, ineligibility for, or refusal of a taxane regimen	Urologie_743	Kramer Gero
FA743A0112	A Phase III, open label, randomized study to assess the efficacy and safety of Olaparib (Lymparza TM) versus Enzalutamide or Abiraterone Acetate in men with metastatic castration-resistant prostate cancer who have failed prior treatment with a new hormonal agent and have homologous recombination repair gene mutations (PROfound)	Urologie_743	Kramer Gero

FA743A0220	Eine multinationale, randomisierte, doppelblinde, placebokontrollierte Phase-III-Studie zur Wirksamkeit und Sicherheit von ODM-201 bei männlichen Hochrisikopatienten mit nicht metastasiertem, kastrationsresistentem Prostatakrebs	Urologie_743	Shariat Shahrokh
FA743A0226	Prostate Cancer Outcomes (PCO) Studie - Eine globale Untersuchung zur Messung und Verbesserung der Ergebnisqualität beim lokal begrenzten Prostatakarzinom	Urologie_743	Shariat Shahrokh
FA743A0261	PSMAfore: A phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of androgen receptor-directed therapy in the Treatment of Taxane Naïve Men with Progressive Metastatic Castrate Resistant Prostate Cancer	Urologie_743	Shariat Shahrokh
FA743A0262	PSMAddition: An International Prospective Open-label, Randomized, Phase III Study comparing 177Lu-PSMA-617 in combination with Standard of Care, versus Standard of Care alone, in adult male patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC).	Urologie_743	Shariat Shahrokh

FA743A0602	Molecular Classification of muscle-invasive bladder cancer patients scheduled for radical cystectomy using a single-sample transcriptomic consensus classifier	Urologie_743	Hassler-Di Fratta Melanie
FA690A0503	Comparison of TTV PCR assays	Virologie_307	Puchhammer Elisabeth
FA690A0602	Induction of HBV Virus neutralizing antibodies in healthy vaccine naive adults and non-responders and in patients chronically infected with HBV Using VVX001	Virologie_307	Aberle Judith
FA690A0704	Überwachung der Respiratorischen Rynzytial Viren in Österreich durch das Diagnostische Influenza Netzwerk Österreich	Virologie_307	Redlberger-Fritz Monika
FA103A0006	RAISE: Dynamics of airway microbionics at pulmonary exacerbation in cystic fibrosis	Vizektorat für Forschung und Innovation_108	Widder Stefanie

Markus Müller

Rektor